2,29 $
5,53 % gestern
Nasdaq, 8. Oktober, 22:00 Uhr
ISIN
US88875G1013
Symbol
TLSA
Berichte

Tiziana Life Sciences PLC Sponsored ADR Aktie News

Positiv
Proactive Investors
8 Tage alt
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said Tuesday it has been invited to present at a major biotechnology conference in Riyadh, underscoring Saudi Arabia's push to position itself as a global hub for life sciences research and investment. The Nasdaq-listed biotech will attend the Life Science Innovation Forum, a two-day event hosted Oct. 1–2 at the King Saud bin Abdulaziz University for Heal...
Neutral
GlobeNewsWire
9 Tage alt
BOSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd.
Positiv
Proactive Investors
13 Tage alt
Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares rose more than 10% in late morning trading on Thursday after the biotech company said it plans to advance development of TZLS-501, an antibody that blocks a key inflammatory pathway.  Tiziana noted that the therapy targets the interleukin-6 receptor, or IL-6R.
Positiv
Proactive Investors
13 Tage alt
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said Thursday it plans to advance development of TZLS-501, an antibody that blocks a key inflammatory pathway, at a time when big drugmakers are paying closer attention to the area. The Boston-based biotech said the therap targets the interleukin-6 receptor, or IL-6R.
Neutral
Proactive Investors
14 Tage alt
Tiziana Life Sciences Ltd (NASDAQ:TLSA) is set to highlight the design of its mid-stage trial for an experimental multiple sclerosis treatment at a leading international neurology conference this week. The biotechnology company said it will present a poster at the 41st Congress of the European Committee for Treatment and Research of Multiple Sclerosis, or ECTRIMS, being held Sept.
Neutral
GlobeNewsWire
15 Tage alt
BOSTON, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd.
Positiv
Proactive Investors
23 Tage alt
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has been awarded a US Department of Defense (DoD) research grant to advance its intranasal anti-CD3 therapy in traumatic spinal cord injury (SCI). The grant will support a three-year study examining the therapy in the acute phase of SCI, focusing on patients who present immediately following injury.
Neutral
GlobeNewsWire
24 Tage alt
BOSTON, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd.

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen